Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T19:57:39.591Z.
Calculation as of: 2026-10-06T19:57:39.591Z.
Quote observation: 2026-10-06T19:55:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
EARNINGS YIELD
N/A
Latigo Biotherapeutics Inc.
Market Cap
$978.09M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.24M
Earnings Yield
6.72%
TTM Avg
5.51%
3Y Avg
5.51%
5Y Avg
5.51%
Market Cap
$979.22M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$971.74M
Earnings Yield
1.42%
TTM Avg
1.18%
3Y Avg
2.75%
5Y Avg
2.30%
Market Cap
$995.51M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
Earnings Yield
N/A
TTM Avg
17.88%
3Y Avg
17.88%
5Y Avg
17.88%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $978.24M | 6.72% | 5.51% | 5.51% | 5.51% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $979.22M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.74M | 1.42% | 1.18% | 2.75% | 2.30% |
| Vor Biopharma Inc. (VOR)vs › | $993.04M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $995.51M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | N/A | 17.88% | 17.88% | 17.88% |
| Savara Inc. (SVRA)vs › | $951.89M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 3.22% | 5.54% | 5.54% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
